Welcome to our dedicated page for CervoMed news (Ticker: CRVO), a resource for investors and traders seeking the latest updates and insights on CervoMed stock.
CervoMed Inc. reports clinical-stage biotechnology developments centered on neflamapimod, an oral small-molecule drug candidate for age-related brain disorders. Company news most often covers dementia with Lewy bodies, the Phase 2b RewinD-LB trial, biomarker and MRI analyses, pharmacokinetic work, formulation and dosing disclosures, and regulatory interactions tied to later-stage development.
Updates also include financial results, grant revenue trends, investor conference presentations, shareholder voting matters, governance items, and capital-structure disclosures. CervoMed has also reported neflamapimod's inclusion in the UK EXPERTS-ALS platform for amyotrophic lateral sclerosis research.
CervoMed (NASDAQ: CRVO) appointed David Quigley to its Board of Directors effective Oct 28, 2025. Mr. Quigley is a former Senior Partner at McKinsey & Company who led Life Sciences and Private Capital practices (Senior Partner 2010–2025) and brings strategy, commercial, transaction, and M&A experience.
The appointment aligns with CervoMed’s near‑term corporate priorities: planned Phase 3 in dementia with Lewy bodies (DLB) and anticipated FDA feedback on Phase 3 design in Q4 2025. Management says Quigley’s network and commercial expertise will support Phase 3 planning, partnering, and potential commercialization of neflamapimod following Phase 2b results.
CervoMed (NASDAQ: CRVO) announced that Matthew Winton, Ph.D., Chief Commercial and Business Officer, will present a corporate presentation at the Emerging Growth Conference on Wednesday, October 22, 2025. The virtual presentation is scheduled for 11:25–11:55 AM ET. A live webcast and replay will be available via the provided webcast link and in the Investor section of the CervoMed website.
CervoMed (NASDAQ: CRVO) reported Phase 2b RewinD-LB results on Oct 8, 2025 showing neflamapimod activity in dementia with Lewy bodies (DLB).
In participants with plasma ptau181 <21 pg/mL (low likelihood of Alzheimer’s co-pathology), NFMD/B produced significant within-subject improvement on CDR-SB versus placebo (difference = −1.12, p=0.005) and improved clinical scales during the first 16 weeks of the Extension Phase. NFMD/B reduced risk of clinically meaningful progression by 67% versus NFMD/A over 32 weeks and 75% versus placebo over 16 weeks (both p<0.001).
Plasma GFAP fell with NFMD/B (median −16.7 pg/mL vs +5.8 pg/mL on placebo; median difference −23.1 pg/mL, p=0.016), and GFAP change correlated with CDR-SB change (p=0.036). The company expects FDA feedback on Phase 3 design in Q4 2025.
CervoMed (NASDAQ: CRVO) appointed Matthew Winton, Ph.D., as Chief Commercial and Business Officer on Oct 7, 2025 to strengthen commercialization and corporate growth as the company advances into late‑stage Phase 3 development for neflamapimod in dementia with Lewy bodies (DLB). Dr. Winton brings nearly two decades of CNS commercial experience, including leadership roles at Biogen and Inozyme and involvement in a recent acquisition. CervoMed granted an inducement option for 75,000 shares at an exercise price of $8.62 on Oct 6, 2025 that vests monthly over three years commencing Oct 31, 2025.
CervoMed (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, announced its participation in the 4th Annual ROTH Healthcare Opportunities Conference in New York, NY.
Company management will join a panel discussion titled "Small Firms Tackling Blockbuster Indications" on Thursday, October 9, 2025, at 8:00 AM ET. The company will also be available for one-on-one meetings with institutional investors during the conference.
CervoMed (NASDAQ: CRVO) highlighted its drug neflamapimod's potential benefits for treating Dementia with Lewy Bodies (DLB) at the 150th Annual American Neurological Association conference. The presentation showcased promising Phase 2b trial results, which demonstrated a significant 74% risk reduction in disease progression compared to placebo in patients with low likelihood of concurrent Alzheimer's Disease pathology.
The company is preparing to initiate a Phase 3 trial for DLB patients and expects to finalize the trial design with the FDA in Q4 2025. The presentation was delivered by Dr. James Galvin, Professor of Neurology and Co-Principal Investigator of the RewinD-LB study.
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, has announced its participation in two upcoming investor conferences in September 2025.
The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, from 2:00 to 2:30 PM ET, with both presentation and one-on-one investor meetings. Additionally, CervoMed will participate in Morgan Stanley's 23rd Annual Global Healthcare Conference from September 8-10, 2025, featuring one-on-one investor meetings.
CervoMed (NASDAQ: CRVO) reported Q2 2025 financial results and provided updates on its Phase 2b RewinD-LB trial for neflamapimod in Dementia with Lewy Bodies (DLB). The 32-week Extension phase data showed a 54% risk reduction in clinical worsening, improving to 64% in patients with minimal Alzheimer's co-pathology.
The company reported $33.5 million in cash and equivalents as of June 30, 2025, with funding runway into Q3 2026. Q2 2025 financial results showed grant revenue of $1.8 million, R&D expenses of $5.1 million, and a net loss of $6.3 million. CervoMed plans to engage with FDA in Q4 2025 to discuss Phase 3 trial design, with trial initiation targeted for mid-2026.
The company also enrolled first patients in Phase 2a trials for acute stroke recovery and frontotemporal dementia.CervoMed Inc. (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, will participate in the Canaccord Genuity 45th Annual Growth Conference in Boston, MA. The company's management will engage in a fireside chat on Tuesday, August 12, 2025, at 2:00 PM ET.
The presentation will be available via webcast, accessible through the company's investor relations website. During the conference, which runs from August 12-14, 2025, management will also conduct one-on-one meetings with investors.
CervoMed (NASDAQ: CRVO) announced positive 32-week data from the Extension phase of the Phase 2b RewinD-LB trial for neflamapimod in treating Dementia with Lewy Bodies (DLB). The trial demonstrated a 54% risk reduction in clinically significant worsening compared to control, improving to 64% in patients with minimal Alzheimer's Disease co-pathology.
Key findings include a significant reduction in plasma levels of glial fibrillary acidic protein (GFAP) at week 32, and improved efficacy with new capsules achieving target plasma concentrations. The study showed a 40% lower rate of clinically meaningful worsening in patients receiving new capsules versus old capsules, with both formulations maintaining similar safety profiles.
CervoMed plans to meet with the FDA in Q4 2025 to discuss Phase 3 trial design for this potential treatment of the second most common form of dementia.